The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: UK stocks rise as Paris and Frankfurt head lower

Thu, 22nd Dec 2022 12:10

(Alliance News) - Stock prices in London were higher at midday on Thursday, ahead of some key US economic data, while equities elsewhere were less buoyant.

The FTSE 100 index was up 34.11 points, 0.5%, at 7,531.43. The FTSE 250 was up 62.80 points, 0.3%, at 18,926.45 , and the AIM All-Share was down just 0.2 of a point, at 830.22.

The Cboe UK 100 was up 0.4% at 752.75, the Cboe UK 250 was up 0.4% at 16,376.71, and the Cboe Small Companies was up 0.1% at 12,933.78.

"The markets seem to be heading into Christmas on a slightly more hopeful note amid signs the US consumer is proving more resilient than feared," said AJ Bell investment director Russ Mould.

This positivity did not extend to European equities, which had fallen into the red by early afternoon Thursday. The CAC 40 in Paris was marginally lower, while the DAX 40 in Frankfurt was down 0.2%.

Consumer confidence in the US economy improved in December, bouncing more than expected as inflation expectations eased and gasoline prices cooled, survey data showed on Wednesday.

The closely watched consumer confidence index rose more than analysts predicted to 108.3 points this month, markedly higher than the revised 101.4 figure in November, said think tank the Conference Board.

There are more US economic indicators to come on Thursday, with US weekly unemployment insurance claims, as well as a gross domestic product print, and personal consumption expenditures.

Annualised US GDP growth is expected to be confirmed at 2.9% in the third quarter.

The dollar was mixed ahead of the data, while stocks in New York were called lower.

Sterling was quoted at USD1.2062 early Thursday, lower than USD1.2093 at the London equities close on Wednesday. The euro traded at USD1.0629, higher than USD1.0612. Against the yen, the dollar was quoted at JPY132.18, firm versus JPY132.08.

The Dow Jones Industrial Average, the S&P 500, and the Nasdaq Composite all were called down 0.3%.

Earlier on Thursday, a new UK GDP print showed a sharper decline in the third quarter than previously forecast.

The UK economy is now estimated to have contracted by 0.3% between July to September. This was downwardly revised from a previous estimate of a 0.2% decline. It mainly reflects revisions to production and construction output estimates, ONS said.

The estimates were adjusted due to the additional bank holiday in September for the state funeral of Queen Elizabeth II, which saw businesses close or reduce their operations.

Meanwhile, annual real UK GDP was revised upwards to 7.6% growth in 2021 from a previous estimate of 7.5%. Despite this, downward revisions in 2022 meant that real GDP is now estimated to be 0.8% below its pre-pandemic size.

This compares with a previous estimate of being just 0.4% below. The estimate shows the UK is the only G7 country to continue to fall short of its pre-pandemic performance.

"There is clearly a caveat in that the UK did shutter shops and close offices and factories to allow people to take time off to pay their respects to the late Queen. But all in all, it's hard to find the silver lining in these gathering storm clouds," said AJ Bell's Danni Hewson.

Gold was quoted at USD1,814.65 an ounce at midday on Thursday, edging down from USD1,815.20 on Wednesday. Brent oil fetched USD83.69 a barrel, higher than USD81.68.

In London, FTSE 100 heavyweights BP and Shell were up 1.7% and 1.0% respectively, tracking the oil price higher.

Amid a more risk-on mood, defensive stocks such as United Utilities and British American Tobacco were succumbing to selling pressure, losing 2.1% and 1.2% respectively.

In the FTSE 250, DiscoverIE was up 1.0%, having returned some of its early morning gain.

The specialised electronic components firm has acquired Magnasphere, a US-based company that designs and manufactures magnetic sensors and switches for industrial electronic purposes. It will pay out USD22 million on a debt-free, cash-free basis before expenses, funded from existing debt facilities.

The acquisition will be immediately accretive to underlying earnings and underlying operating margin, discoverIE said.

"This acquisition of Magnasphere continues our strategy of building a differentiated, international, growth-focused electronics group with strong operating margin," said discoverIE Chief Executive Nick Jefferies.

On AIM, Tekmar surged up 50%.

The offshore energy markets services and technology provider won a new contract to supply cable protection systems to phase three of the UK's Dogger Bank C wind farm. The award comes from DEME Offshore.

The 3.6 gigawatt wind farm is located off the north east coast of England. Tekmar will design, manufacture and supply a further 172 CPS, having already supplied 380 CPS in the A and B project phases at Dogger Bank. It provided no financial details.

Destiny Pharma also added 10%.

The clinical-stage biotechnology company, said the completion of a partnering agreement for its NTCD-M3 phase 3 drug is expected in early 2023.

The company said it had entered exclusive negotiations with a US pharmaceutical company to secure a commercialisation partner for NTCD-M3 - its lead asset for the prevention of clostridioides difficile infection recurrence.

Thursday is the last full day of trading in London before Christmas, before an early finish at 1230 GMT on Friday.

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.